The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
1 report, 1 independent
Updated Sep 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Central government utilizes the Department of Pharmaceuticals (DoP) for market oversight, discussing systematic price reconciliation via DPCO, as the FDA flags price gaps between trade and MRPs.Sub-event
FDA is monitoring drug industry practices and pricing, utilizing JAMA studies.1 source
Keep exploring
The entities involved
Related events
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA is currently reviewing new drug applications for market entry.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.